Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$2.51 +2.0%	$2.57	$7.96 ▼ $24.15	$12.66M	0.63	15,685 shs	67,710 shs
COEP Coeptis Therapeutics	$13.46 +0.2%	$10.14	$2.31 ▼ $14.70	$64.88M	-0.59	52,938 shs	43,507 shs
KLRS Kalaris Therapeutics	$2.51 +2.0%	$2.56	$2.14 ▼ $24.15	$46.94M	0.49	47,049 shs	67,709 shs
STTK Shattuck Labs	$0.96 +7.3%	$0.86	$0.69 ▼ $3.95	$45.99M	1.63	5.25 million shs	489,082 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	+2.03%	+2.03%	-9.39%	-10.04%	-85.81%
COEP Coeptis Therapeutics	0.00%	-3.65%	+13.01%	+29.30%	+217.45%
KLRS Kalaris Therapeutics	0.00%	+2.03%	-11.62%	-10.04%	+250,999,900.00%
STTK Shattuck Labs	0.00%	-4.00%	+10.46%	-11.11%	-72.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	0.7098 of 5 stars	0.0	3.0	0.0	0.0	2.7	1.7	0.0
KLRS Kalaris Therapeutics	1.2731 of 5 stars	2.0	0.0	0.0	0.0	1.6	3.3	0.6
STTK Shattuck Labs	3.5104 of 5 stars	3.4	5.0	0.0	0.0	2.4	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	19.52% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.00	629.17% Upside

Current Analyst Ratings Breakdown

Latest ALVR, COEP, STTK, and KLRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$4.00 ➝ $2.00
8/14/2025	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
COEP Coeptis Therapeutics	$263.56K	246.16	N/A	N/A	$1.47 per share	9.16
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
STTK Shattuck Labs	$5.72M	8.04	N/A	N/A	$1.19 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	11/10/2025 (Estimated)
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-201.73%	-108.46%	N/A
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A
STTK Shattuck Labs	-$75.41M	-$1.21	N/A	N/A	N/A	N/A	-81.80%	-71.46%	N/A

Latest ALVR, COEP, STTK, and KLRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/14/2025	Q2 2025	STTK Shattuck Labs	-$0.25	-$0.24	+$0.01	-$0.24	N/A	N/A
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
COEP Coeptis Therapeutics	0.02	0.83	0.82
KLRS Kalaris Therapeutics	N/A	11.98	11.98
STTK Shattuck Labs	N/A	10.25	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
COEP Coeptis Therapeutics	13.88%
KLRS Kalaris Therapeutics	66.05%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
COEP Coeptis Therapeutics	24.25%
KLRS Kalaris Therapeutics	74.99%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
COEP Coeptis Therapeutics	2	4.82 million	3.65 million	Not Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
STTK Shattuck Labs	100	47.90 million	42.16 million	Optionable

ALVR, COEP, STTK, and KLRS Headlines

Recent News About These Companies

Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 22 at 10:45 AM | finanznachrichten.de

Shattuck Labs says IND for SL-325 for treatment of IBD in effect

August 22 at 10:45 AM | msn.com

Shattuck Labs Reports Q2 2025 Financial Results

August 22 at 10:45 AM | msn.com

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 21 at 10:17 AM | globenewswire.com

Shattuck Labs raises up to $103M to fund therapeutic antibody development

August 19, 2025 | ncbiotech.orgN

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Estimates Shattuck Labs Q1 Earnings

August 18, 2025 | americanbankingnews.com

Shattuck Labs' (STTK) "Hold" Rating Reiterated at Needham & Company LLC

August 17, 2025 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Price Target Lowered to $2.00 at Leerink Partners

August 16, 2025 | americanbankingnews.com

Shattuck Labs price target lowered to $2 from $4 at Leerink

August 14, 2025 | msn.com

Shattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025

August 14, 2025 | quiverquant.comQ

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Shattuck Labs expects $103 million from private placing

August 6, 2025 | thepharmaletter.comT

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

August 5, 2025 | globenewswire.com

Shattuck Labs Elects Directors, Approves Auditor at Meeting

July 15, 2025 | tipranks.com

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR, COEP, STTK, and KLRS Company Descriptions

AlloVir NASDAQ:ALVR

$2.51 +0.05 (+2.03%)

As of 08/22/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Coeptis Therapeutics NASDAQ:COEP

$13.46 +0.03 (+0.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.50 +0.04 (+0.30%)

As of 08/22/2025 07:19 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Kalaris Therapeutics NASDAQ:KLRS

$2.51 +0.05 (+2.03%)

As of 08/22/2025 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Shattuck Labs NASDAQ:STTK

$0.96 +0.07 (+7.30%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.94 -0.02 (-2.08%)

As of 08/22/2025 06:17 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time